FDA sent a warning letter to Kyowa Hakko Bio Co., Ltd. after inspectors found data integrity problems at the company’s Yamaguchi, Japan facility.
FDA sent a warning letter, dated Aug. 10, 2018, to Kyowa Hakko Bio Co., Ltd. after an inspection of the company’s Yamaguchi, Japan facility found current good manufacturing practice (CGMP) violations. During the inspection, which occurred from Sept. 4–8, 2017, inspectors found data integrity deviations, including the manipulation of data.
The warning letter stated that the company had performed retesting or had manipulated data after obtaining out-of-specification (OOS) results. The company told the agency that data were manipulated to meet nonconforming system suitability tests (SST) for high-performance liquid chromatography (HPLC) analysis of raw materials. “You attributed the root cause to your firm’s ‘lack of awareness of the seriousness’ of CGMP deviations, and to an ‘environment where test data could be easily manipulated.’ Your investigation stated that you reanalyzed the crude sample and concluded that it met the specification. You provided no further details on the root causes and on the effect of using a system that failed SST to test your raw material,” the agency stated in the letter. FDA asked the company to provide an assessment of the company’s quality system and perform a retrospective review of all distributed lots.
Lack of data integrity control was also cited by the FDA investigators. The agency stated that controls over HPLC systems were inadequate, and unprotected Excel worksheets were used to perform calculations and statistical evaluations of production data. “These electronic files were not secured to prevent unauthorized changes and have no change history. Your firm’s lack of data control calls the reliability of your data into question,” the agency stated. FDA asked the company to provide a review of its controls and procedures and provide a detailed corrective action and preventive action plan. The agency also detailed steps the company should take to complete data integrity remediation.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.